Tests stent plus intensive medicine to prevent repeat stroke from brain artery narrowing
Tests a stent with intensive medicine in adults with narrowed brain arteries.
Plain-language title generated from the registry record
Registry title: Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
Key facts
- Where
- Baotou, Beijing, Benxi, Cangzhou, Changchun, Hangzhou, Hohhot, Lishui, Nanjing, Ningbo, Taiyuan, Tangshan, Tongliao, Wuhai, Wuhan, and Xingtai, ChinaSee the 18 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a stroke in the last 30 days caused by a severely narrowed artery inside the brain.
- Age
- 18 to 85 years
- Sex
- All sexes can join
- Disease stage
- Ischemic stroke within 30 days of enrolment, caused by 70% to 99% narrowing of a major artery inside the brain. The target vessel is 2.0mm to 4.5mm wide and the narrowed part is 14 mm long or shorter. Disability score (mRS) 3 or lower.
- Earlier treatment
- No earlier stent in an artery of the brain. Must be able to take two blood-thinning drugs together (dual antiplatelet therapy).
Main reasons for not taking part
- Stroke within 7 days before enrolment
- Bleeding in or around the brain in the past 6 weeks
- Narrowing not caused by atherosclerosis, for example Moyamoya disease or vasculitis
- Clear source of blood clots in the heart
- Pregnant or breastfeeding women
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT04948749, who can take part
Where in China
- Baotou Central HospitalBaotou, ChinaTaking people
- Beijing Daxing District People's HospitalBeijing, ChinaTaking people
- Beijing Tiantan HospitalBeijing, ChinaTaking people
- General Hospital of Benxi Iron and Steel CoBenxi, ChinaTaking people
- Hejian People's HospitalCangzhou, ChinaTaking people
- The Second Norman Bethune Hospital of JilinUniversity,Changchun, ChinaTaking people
- The First Affiliated Hospital of College of MedicineHangzhou, ChinaTaking people
- Inner Mongolia Autonomous Region People's HospitalHohhot, ChinaTaking people
- Lishui People's HospitalLishui, ChinaTaking people
- The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaTaking people
- Beilun People's Hospital of Ningbo CityNingbo, ChinaTaking people
- Shanxi Cardiovascular HospitalTaiyuan, ChinaTaking people
- Shanxi Provincial People's HospitalTaiyuan, ChinaTaking people
- North China University of Science and Technology Affiliated HospitalTangshan, ChinaTaking people
- Tongliao City HospitalTongliao, ChinaTaking people
- Wuhai People's HospitalWuhai, ChinaTaking people
- General Hospital of The Yangtze River ShippingWuhan, ChinaTaking people
- Xingtai City Third HospitalXingtai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT04948749
- Record updated
- 15 July 2026
- Original description
The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.Read full original descriptionShow less
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE)
The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.
Inclusion: Age from 18 to 85 years; Patients with ischemic stroke within 30 days of enrolment attributed to 70% to 99% stenosis of a major intracranial artery (internal carotid artery [C5-C7], middle cerebral artery [M1], vertebral artery [V4], or basilar artery) on CTA (According to WASID method); The diameter of the target vessel between 2.0mm - 4.5mm; The stenosis lesion length ≤ 14 mm; Baseline modified Rankin Scale (mRS) score ≤ 3; Patient understands the purpose and requirements of the study, and has provided informed consent.
Exclusion: Ischemic stroke occurred within 7 days before enrolment; Cannot tolerate dual antiplatelet therapy; Major surgery within the past 30 days or planned within 90 days; Stroke caused by perforating artery occlusion; Any history of brain parenchymal or subarachnoid, subdural or extradural haemorrhage in the past 6 weeks; Intracranial artery stenosis caused by non-atherosclerotic lesions, including: arterial dissection, Moyamoya disease, vasculitis disease, herpes zoster, varicella-zoster or other viral vascular diseases, neurosyphilis, any other intracranial infections, any intracranial stenosis related to cerebrospinal fluid cells, radiation-induced vascular disease, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, central nervous system benign vascular disease, postpartum vascular disease, suspected vasospasm, suspicious embolism recanalization, etc; History of stenting of an intracranial artery; Presence of any unequivocal cardiac source of embolism; Cannot complete the follow-up due to cognitive, emotional or mental illness; Hemoglobin<100g/L, platelet count <100×109/L; INR>1.5 or there are uncorrectable factors leading to bleeding; Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal or distal to the target intracranial lesion (NOTE: an exception is allowed if stenosis or occlusion involves a single vertebral artery proximal to a symptomatic basilar artery stenosis and the contralateral vertebral artery is supplying the basilar artery); Bilateral intracranial vertebral artery stenosis of 70%-99% and uncertainty about which artery is symptomatic (NOTE: an exception is that if bilateral vertebral arteries with 70%-99% stenosis but unequal in size, the dominant side is considered as symptomatic); Unilateral vertebral artery stenosis of 70%-99% with normal contralateral vertebral artery; CT angiographic evidence of severe calcification at target lesion; Combined with intracranial tumor, aneurysm or intracranial arteriovenous malformation; Contraindications to heparin, rapamycin, contrast and local or general anesthesia; Severe hepatic and renal dysfunction; Renal artery, iliac artery, and coronary artery requiring simultaneous intervention; Life expectancy <1 year; Pregnant or lactating women; Other situations that are not suitable for enrolment according to the judgement of the investigator; Enrolment in another study that would conflict with the current study.